Investigating Safety, Tolerability and Efficacy of AZD5363 in Prostate Cancer.
| Status: | Completed |
|---|---|
| Conditions: | Prostate Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 5/5/2014 |
| Start Date: | October 2012 |
| End Date: | February 2015 |
| Contact: | AstraZeneca Clinical Study Information |
| Email: | ClinicalTrialTransparency@astrazeneca.com |
| Phone: | 800-236-9933 |
A Phase Ib Multicentre Study of AZD5363 Monotherapy to Assess Anti-Tumour Activity,Safety,Tolerability,and Pharmacokinetics in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC)(PYRUS)
To investigate the safety, tolerability and anti-tumour activity of AZD5363, as monotherapy,
in patients with metastatic Castrate-Resistant Prostate Cancer. AZD5363 will be investigated
in patients who have progressed after chemotherapy (Part A) and in patients who have
progressed before receiving chemotherapy (Part B).
Recruitment into Part A, Group 1 has been suspended. A new design for this group is
currently being evaluated. Part A, group 2 patients (progressed after 1 or more 2nd
generational anti-hormonal therapies) will receive AZD5363 480mg bid intermittently (4 days
on/3days off).
Part B will only start if there is evidence of anti-tumour activity along with AZD5363
having an acceptable safety profile in Part A. Part B will be conducted in pre-chemotherapy
patients on a dose and schedule selected from Part A.
in patients with metastatic Castrate-Resistant Prostate Cancer. AZD5363 will be investigated
in patients who have progressed after chemotherapy (Part A) and in patients who have
progressed before receiving chemotherapy (Part B).
Recruitment into Part A, Group 1 has been suspended. A new design for this group is
currently being evaluated. Part A, group 2 patients (progressed after 1 or more 2nd
generational anti-hormonal therapies) will receive AZD5363 480mg bid intermittently (4 days
on/3days off).
Part B will only start if there is evidence of anti-tumour activity along with AZD5363
having an acceptable safety profile in Part A. Part B will be conducted in pre-chemotherapy
patients on a dose and schedule selected from Part A.
A Phase Ib Multicentre Study of AZD5363 Monotherapy to Assess Anti-Tumour Activity, Safety,
Tolerability, and Pharmacokinetics in Patients With Metastatic Castrate-Resistant Prostate
Cancer (mCRPC) (PYRUS)
Tolerability, and Pharmacokinetics in Patients With Metastatic Castrate-Resistant Prostate
Cancer (mCRPC) (PYRUS)
Inclusion Criteria:
- Provision of informed consent
- Males aged 18 years and older
- Histologically confirmed adenocarcinoma of the prostate without neuroendocrine
differentiation or small cell features for which no standard therapy is currently
considered appropriate
- Documented evidence of Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
- Part A: Patients must have received prior docetaxel-based chemotherapy for mCRPC and
have a Circulating Tumour Cell score of 5;
- Part B: Patients must have progressed before receiving any chemotherapy for mCRPC;
Exclusion Criteria:
- Any prior exposure to agents which inhibit AKT as the primary pharmacological
activity
- Any evidence of severe or uncontrolled systemic diseases, including uncontrolled
hypertension, active bleeding diatheses, or active infection including hepatitis B,
hepatitis C, and human immunodeficiency virus
- Spinal cord compression or brain metastases unless asymptomatic, treated, and stable
and not requiring steroids
- Clinically significant abnormalities of glucose metabolism
- Major surgery within the previous 4 weeks
We found this trial at
5
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials